SPONSORED CONTENT

Hyderabad based BioGenex develops Direct RT-PCR Kit which detects all variants of Covid-19 Double Quick

January 13, 2022 15:30 IST | ANI Press Release
Tennis player James Blake
BioGenex

Hyderabad (Telangana) [India], January 13 (ANI/BusinessWire India): BioGenex Life Sciences Pvt Ltd. has developed a RT-PCR kit for Covid-19 diagnosis, which detects COVID 19 caused by SARS COV 2 variants including "OMICRON" plus other variants.

The NIB, Noida, an ICMR designated lab, examined the performance of this kit and found that it performed with 100% accuracy which means no false negatives or positives, which will significantly control the pandemic through accurate diagnosis. The kit detects Omicron variant in half the time than standard RT-PCR test.

The TRIPLEX COVID-19 RT-PCR Direct is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 directly from the upper respiratory swab, nasopharyngeal or oropharyngeal swabs, collected in preservative media, (VTM/UTM), pH 7.2-7.4 to provide the molecular diagnostic basis for infected patients.

This test analyses samples in VTM directly without the need for RNA extraction step. It helps scientists for rapid tracking of disease prevalence and aid in treatment insight (e.g. hospital beds, oxygen ventilators and expensive medications) for healthcare systems in making appropriate measures to combat COVID-19.

There are many challenges associated with ramping up testing capacity, due to supply chain delays and shortage of extraction reagents, this situation call-up for alternative protocols to ensure the continuity of testing in laboratories. Due to increased demand for SARS-CoV-2 variants screenings, an alternative protocol with similar sensitivity is required, said Dr. Krishan Kalra, CEO BioGenex.

He further added, "Sustained surveillance is essential for public health. Our latest tests reduce the cost of testing and turnaround time for the result. As we learn from the pandemic, we are partnering with concerned organizations to understand and strengthen our diagnostic portfolio to develop-deliver reliable and sustainable diagnostic solutions in the future."

For more info on COVID 19 products please visit: (https://ingenuityd.com). IngenuityD is a special spinoff from BioGenex which caters to COVID 19 diagnostic market.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Hyderabad based BioGenex develops Direct RT-PCR Kit which detects all variants of Covid-19 Double Quick

Hyderabad (Telangana) [India], January 13 (ANI/BusinessWire India): BioGenex Life Sciences Pvt Ltd. has developed a RT-PCR kit for Covid-19 diagnosis, which detects COVID 19 caused by SARS COV 2 variants including "OMICRON" plus other variants.

The NIB, Noida, an ICMR designated lab, examined the performance of this kit and found that it performed with 100% accuracy which means no false negatives or positives, which will significantly control the pandemic through accurate diagnosis. The kit detects Omicron variant in half the time than standard RT-PCR test.

The TRIPLEX COVID-19 RT-PCR Direct is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 directly from the upper respiratory swab, nasopharyngeal or oropharyngeal swabs, collected in preservative media, (VTM/UTM), pH 7.2-7.4 to provide the molecular diagnostic basis for infected patients.

This test analyses samples in VTM directly without the need for RNA extraction step. It helps scientists for rapid tracking of disease prevalence and aid in treatment insight (e.g. hospital beds, oxygen ventilators and expensive medications) for healthcare systems in making appropriate measures to combat COVID-19.

There are many challenges associated with ramping up testing capacity, due to supply chain delays and shortage of extraction reagents, this situation call-up for alternative protocols to ensure the continuity of testing in laboratories. Due to increased demand for SARS-CoV-2 variants screenings, an alternative protocol with similar sensitivity is required, said Dr. Krishan Kalra, CEO BioGenex.

He further added, "Sustained surveillance is essential for public health. Our latest tests reduce the cost of testing and turnaround time for the result. As we learn from the pandemic, we are partnering with concerned organizations to understand and strengthen our diagnostic portfolio to develop-deliver reliable and sustainable diagnostic solutions in the future."

For more info on COVID 19 products please visit: (https://ingenuityd.com). IngenuityD is a special spinoff from BioGenex which caters to COVID 19 diagnostic market.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22